Table 1.
Clinical and biochemical characteristics in different groups. (χ ± s)
| Control-a | Control-b | IBD before treatment | ||
|---|---|---|---|---|
| UC | CD | |||
| Number of subjects | 50 | 30 | 23 | 25 |
| Age (years) | 33 ± 11.5 | 33.9 ± 2.9 | 34.3 ± 12.3 | 36.7 ± 10.8 |
| Smoker [n (%)] | 3 (6 %) | 3 (10 %) | 2 (8.6 %) | 3 (12 %) |
| Sex (M/F) | 20/30 | 17/13 | 11/12 | 12/13 |
| SBP (mm Hg) | 118.3 ± 11.8 | 101.3 ± 12.3 | 120.8 ± 14.5 | 125.3 ± 11.8 |
| DBP (mm Hg) | 72.2 ± 13.2 | 73.1 ± 10.5 | 70.7 ± 12.6 | 77.2 ± 15.1 |
| BMI (kg/m2) | 23.5 ± 7.1 | 22.12 ± 5.1 | 25.9 ± 2.1 | 24.5 ± 3.2 |
| FPG (mmol/l) | 4.31 ± 2.34 | 4.51 ± 1.66 | 5.09 ± 1.67 | 5.26 ± 1.23 |
| TC (mmol/l) | 4.08 ± 1.55 | 3.95 ± 1.35 | 4.37 ± 1.56 | 4.29 ± 1.43 |
| LDL-C (mmol/l) | 2.32 ± 0.62 | 2.52 ± 0.65 | 2.67 ± 0.55 | 2.45 ± 1.09 |
| HDL-C (mmol/l) | 1.78 ± 0.31 | 1.99 ± 0.77 | 1.25 ± 0.89 | 1.11 ± 0.56 |
| TG (mmol/l) | 1.52 ± 0.62 | 1.81 ± 0.86 | 1.75 ± 0.86 | 1.91 ± 1.09 |
| HbA1C (%) | 4.13 ± 1.23 | 4.34 ± 1.56 | 4.75 ± 1.08 | 4.62 ± 1.05 |
| Uric acid (umol/l) | 313.6 ± 27.9 | 333.8 ± 33.6 | 309.1 ± 27.9 | 318.5 ± 25.1 |
| Urine Albumin (mg/l) | 12.9 ± 6.4 | 15.6 ± 8.7 | 10.7 ± 7.9 | 13.6 ± 8.5 |
| HOMA-IR | 2.25 ± 1.45 | 2.05 ± 1.35 | 3.93 ± 1.65*♀ | 4.17 ± 1.66 *♀ |
| Asprosin (ng/ml) | 28.38 ± 7.11 | 27.11 ± 6.45 | 17.89 ± 7.22*♀ | 12.77 ± 9.09*♀# |
| CCDC80 (ng/ml) | 1.15 ± 0.33 | 1.35 ± 0.78 | 1.78 ± 1.68*♀ | 2.33 ± 1.86*♀# |
| ANGPTL4 (pg/ml) | 42.13 ± 5.12 | 45.35 ± 6.12 | 25.11 ± 12.21*♀ | 20.56 ± 13.77*♀# |
| CRP (mg/l) | 1.08 ± 0.89 | 2.15 ± 1.07 | 3.97 ± 0.67** | 4.06 ± 0.86**♀ |
| ESR (mm/h) | 3.3 ± 1.32 | 5.12 ± 1.67 | 17.11 ± 2.66** | 14.88 ± 3.79**♀ |
| Disease activity | - | - | 6.86 ± 2.67 | 278.23 ± 35.23 |
| Duration of symptoms (year) | - | - | 3.21 ± 1.52 | 4.12 ± 2.12 |
| Baseline flow (ml/min) | 80.55 ± 36.23 | 83.15 ± 31.55 | 81.23 ± 25.77 | 86.33 ± 26.67 |
| GTN-induced dilation (%) | 23.12 ± 5.01 | 25.55 ± 3.77 | 26.37 ± 6.55 | 22.56 ± 3.11 |
| FMD (%) | 5.65 ± 1.01 | 5.71 ± 1.67 | 3.51 ± 2.23*♀ | 3.22 ± 1.57**♀ |
| Baseline vessel (mm) | 4.03 ± 1.12 | 4.15 ± 2.08 | 3.69 ± 1.33 | 3.92 ± 1.28 |
*
p < 0.05,
**
p < 0.01, compared with control-a,
♀
p < 0.05,
♀♀
p < 0.01, compared with control-b,
#
p < 0.05,
##
p < 0.01, UC vs. CD.
ANGPTL4, angiopoietin-like 4; CCDC80, coiled-coil domain-containing 80; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FPG, fasting glucose; FMD, flow-mediated dilation; HOMA-IR, homeostasis model assessment of insulin resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride;